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The main objective of this retrospective study is to analyze the future of
heart failure patients, refractory to optimal pharmacological treatment,
implanted by a bi-ventricular pacemaker (CRT-P) or defibrillator (CRT-D).
Methods: 340 patients were implanted between the 1st January 1999 and
31 December 2007, aged 69 +/-10 years mainly men (80%). The total popula-
tion presented in part ischemic heart disease (56%), NYHA class III (79%)
and an indication of primary prevention (76%). The number of hospitalization
in the 6 months prior to implantation is an average of 1 +/- 1. The population
was divided into 3 groups: 
Group 1: 194 patients responders [R] (decrease of NYHA class, or stable
NYHA and decreasing hospitalization, or the latter stable and increasing the
LVEF of more than 10%, 6 months after implantation), 
Group 2: 84 patients not responders [NR] (do any of the above criteria),
Group 3: 62 patients very good responders [SR] with the increasing LVEF
greater than 15%.
Results: The comparison between the 3 groups showed a significant differ-
ence for the follow parameters: the NYHA class ([NR] 2.8 +/- 0.6 vs [R] 2.0
+/- 0.4 vs [SR] 1.8 +/- 0.5 ), the number of hospitalization ( [NR] 1.1 +/- 1.3
vs [R] 0.2 +/- 0.5 vs [SR] 0.1 +/-0.3 ), LVEF ( [NR] 29 +/- 9 vs [R] 33 +/- 8
vs [SR] 47 +/- 8 ). The curves of Kaplan-Meyer show a significant difference
in survival rates for non-responders, responders and good responders (Logrank
p <0.001).
Discussion: Treatment with bi-ventricular stimulation shows that 75% of
patients are improved compared to the criteria usually measured. The study
reveals a group of very good responders representing 18% of the total popula-
tion with a survival rate at 5 years over 65%.
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Background: Oxidative stress (OS) implication is paramount in pathology:
ischemia reperfusion sequence (acute coronary syndrome, cardiac surgery,
transplantation). Involvement of OS in heart failure (HF) is less known but is
increased in the failing heart, and this might contribute to the pathogenesis of
myocardial remodeling and HF.
Aim: Prospective study to identify OS in plasma from patients with a cardio-
genic shock and to evaluate the role of etiologies of cardiomyopathy: ischemia
or no.
Methods: Consecutive patients hospitalized in the cardiology unit with a
first cardiogenic shock that complicated an idiopathic or ischemic dilated car-
diomyopathy (DCM) with left ventricular (LV) dysfunction.
Exclusion criteria: known cardiomyopathy, acute coronary syndrome,
septic or anaphylactic or hypovolemic shock, treatment with angiotensin
converting enzyme inhibitors (ACEI) or angiotensin II antagonists (AA II).
OS was evaluated in blood samples at the admission (T0) and one month
later: thiobarbituric acid-reactive substances (TBARS), total antioxidant status
(TAS), protein carbonyls (PC) and LDL oxidized; superoxide dismutase
(SOD), glutathione peroxidase(GSH and GSSG/GSH) and catalase activities;
plasma α tocopherol, vitamin A and β carotene.
Results: 23 consecutive patients (90% men), mean age 59±11y. Follow-up
of 15 months. The aetiologies of CMD were ischemic (n=6), idiopathic
(n=15), toxic (n=1) or restrictive (n=1). The mean LV ejection fraction was
23.3±8%. The NT-proBNP level was 9600±2000ng/ml.
Acute heart failure was associated with an increased OS. OS was more
important in patients with arrhythmia.
Conclusion: Acute heart failure increased the level of oxygen free radi-
cals. We hypothetized that modifications of OS could be implied in arrhyth-
mias and complications of acute heart failure.
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Rationale: Beta blockers are a corner stone treatment of heart failure (HF)
in patients with altered systolic function (LVEF<40%). Guidelines are less
clear for HF patients with preserved systolic function (LVEF>50%) or for
patients belonging to the “grey zone” (LVEF 40-50%).
Objectives: to describe the prescription rate of beta-blockers in HF patients.
Methods: Cross sectional observational survey with retrospective collec-
tion of data at hospital discharge. Patients must have been diagnosed with
CHF and have been hospitalised for CHF within the previous 18 months.
Patients are classified according to the LVEF at hospital discharge.
Results: 1 452 patients were included by 412 French outhospital cardiolo-
gists. 1137 with known LVEF at hospital discharge have had at least one visit
by the cardiologist between hospital discharge (mean delay 5.76±4.51
months). In a multivariate model, BB prescription was more frequent in HF
from ischemic origin (OR=1.39) or with dilated cardiomyopathy (OR=1.44)
and less frequent in older patients (OR=0.97 per year) and in case of asthma/
COPD (OR=0.31 and if FEVG was >50% (OR=0.62).
 TO 1 MONTH
NORMAL 
VALUE
PC (μmol/g prot) 0.16 (0.05-0.41) 0.14 (0.07-0.29) < 0.10
TBARS (nmol/gHb) 2.2 (1.3-17.3) 2.5 (1.1-6.5) 0.7-1.6
LDLox (UI/L) 48 (20-83) 49 (26-98) 16-18
GSH (μmol/g Hb) 2.1 (0.8-3.1) 2.2 (1.7-4) 3.3-6.9
GSSG/GSH 0.19 (0.09-0.93) 0.13 (0.07-0.29) < 0.08
 
 
LVEF < 40%
N=661
LVEF 40-50%
N=282
LVEF > 50%
N=194
Total
N=1137
At hospital discharge/at entry in the survey
BB 78%/83% 78%/85% 62%/70% 76%/82%
Recommended BB† 75%/77% 72%/74% 54%/62% 71%/74%
 Reaching the target 
dose
8%/16% 7%/16% 7%/13% 7%/15%
Changes since discharge
 BB added* 28% 34% 25% 28%
 BB stopped** 1% 1% 2% 1%
 BB dose increased* 27% 27% 17% 25%
 BB dose decreased 4% 1% 3% 3%
†metoprolol, nebivolol, bisoprolol, carvedilol ; 
*percentage calculated in patients without BB at hospital discharge (N=278); 
** percentage calculated in patients with BB at hospital discharge (N=859).
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Conclusion: Rate of betablockers prescription is high at hospital discharge.
Outhospital cardiologists not only pursue but also amplify the care strategies
defined during hospitalisation increasing the proportion of patients receiving
BB and the percentage reaching the target dose.
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Rationale: Heart failure (HF) treatment is often started during hospitalisation
and patients are generally taken over after discharge by outhospital cardiologists.
Objectives: To describe changes in HF treatment implemented by the out-
hospital cardiologist after hospital discharge.
Methods: Cross sectional observational survey with retrospective collec-
tion of data at hospital discharge. Patients must have been diagnosed with HF
and hospitalized for HF within the previous 18 months.
Results: 1 452 patients were included by 412 French outhospital cardiolo-
gists. 1170 have had at least one visit by the cardiologist between hospital dis-
charge (mean delay 5.76±4.51 months). At hospital discharge, target doses
were reached in 10.5% of patients receiving betablockers, 50.9% of patients
with ACEI and in 4.1% of patients with ARB. Doses were increased in 25.3%
of patients receiving betablockers, in 11.7% of patients receiving ACEI and in
10.3% of patients treated with ARB enabling a target dose in 20.4% of patients
with betablockers, and in 83.2% of patients with ACEI or an ARB.
Table. Evolution of treatment after discharge 
Conclusion: Outhospital cardiologists play a critical role in care manage-
ment of HF patients. Not only do they implement but they also amplify the
care strategies defined during hospitalisation.
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Bortezomib is an antitumor therapy for Multiple Myeloma and Non
Hodgkin Lymphoma which incidence is dramatically growing up. This drug
inhibits proteasome activity through action on the 26 S proteasome in mam-
malian cells and leads to apoptosis of tumoral cells. Cardiac toxicity of this
drug is not clearly established and its mechanistic poorly understood. More-
over, the few reports in the update literature are unable to prove a direct
involvement of bortezomib in the occurrence of Acute or Chronic Heart
Failure.
We report the first clinical observation of chronic heart failure which
can be directly related to administration of bortezomib. This relationship is
strongly suggested by the pharmacological Begaud’s score for drug
adverse events with a high degree of imputability. This observation is fur-
ther supported by the report of all other cases of cardiac failure associated
with bortezomib, reported in the French pharmacovigilance database
(table 1).
These reports, the largest cohort available in the international literature,
should lead to a systematically screening for asymptomatic cardiac dis-
eases as well as a rigorous follow up of patients exposed to bortezomib.
The strength of our report is i/ the identification of a case for which the
direct role of bortezomib was demonstrated, ii/ to emphasize with our case
series that this effect occurs more frequently than suspected with a serious
outcome. At hospital 
discharge
At start 
of the survey
Medication 
prescribed 
after discharge
Medication 
discontinued 
after discharge
Betablocker 826 (70,6%) 863 (73,8%) 87 (25,3%)* 50 (6,1%)*
ACEI†† 807 (69,0%) 788 (67,4%) 46 (12,7%)* 65 (8,1%)**
ARB‡ 170 (14,5%) 210 (18,0%) 56 (5,6%)* 16 (9,4%)**
ACEI or ARB 961 (82,1%) 973 (83,2%) - -
*percentages calculated on the number of patients without the treatment 
at hospital discharge;
** percentages calculated on the number of patients without the treatment 
at hospital discharge;†metoprolol, nebivolol, bisoprolol, carvedilol;
††captopril, enalapril, lisinopril, trandolapril, ramipril, perindopril 
(at an accepted target dose of 4mg);‡candesartan, valsartan 
Table 1.  (090)
Patients Age (Year) Gender Disease Cardiac Risk Factor
Prior 
Chemotherpy 
regimens
N°bortezomib 
containing 
cycles
Cumulated 
Dose 
(mg/m2)
Cardiac 
complication death Imputability
#1 79 F MM HTA 0 1 2,64 Acute Heart Failure yes I3
#2 79 F MM 0 1 6 31,2 Acute Heart Failure No I1
#3 71 F MM 0 0 6 31,2 Acute Heart Failure  No I1
#4 54 F MM 0 2 1 4,45 Cardiogenic Shock Yes I1
#5 74 M MM 0 0 1 3,9 Acute Heart Failure Yes I4
#6 61 F MM HTA 4 10 54,3 Acute Heart Failure No I1
#7 69 F MM 0 0 3 15,6 Acute Heart Failure No I1
#8 54 M MM 0 5 3 15 ,6 Acute Heart Failure No I1
Data from the French Pharmacovigilance Database
